Sorivudine

N/A

Report date: 2024/06/27 20:00:09
NME

Base Information

Drug NameSorivudine
Drug Alias Name索立夫定BVAUBV-ara-U索利夫定sorivudinum +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsNeuralgia, PostherpeticHerpes ZosterChickenpox +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEisai Co LtdAlfresa PharmaBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyArigen Pharmaceuticals IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsNeuralgia, PostherpeticHerpes ZosterChickenpox +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG